Application of Recombinant Activated Factor Ⅶ in Orthotopic Liver Transplantation

张雅敏,朱志军,曲伟,蔡金贞,侯建存,沈中阳
DOI: https://doi.org/10.3760/cma.j.issn.1001-9030.2009.02.040
2009-01-01
Abstract:Objective To access the clinical effect of recombinant activated factor Ⅶ (rFⅦa) in orthotopic liver transplantation. Methods Sixty patients were randomized to rF Ⅶ a treatment group or control group. A bolus of rFⅦa was administered in the study group 15 min before operation,whereas pla-cebo in control group intravenously. Coagulation variables were recorded at described time points. Blood loss, transfusion requirements, vascular complication and hospital cost were compared between two groups. Results In contrast with the control group, the perioperative blood loss and transfusion of RBC, FFP re-quirements were significantly reduced [(1245 ± 496) ml, ( 6.31 ± 4.86 ) U, (952 + 814) ml vs ( 2496± 1713) ml, ( 10.34 ± 5.36 ) U. ( 1849 ± 674 ) ml, respectively, P < 0. 01], but there was no significant difference in the activated partial thromboplastin time (APTT) ,fibrinogen (FIB), platelet count (PLT). hemoglobin(HB) and hospital cost between two groups ( P > 0.05 ). Conclusion Single pretransplant bolus of rFⅦa can rapidly improve the exogenous coagnlation function, obviously reduce operation bleeding and transfusion requirements, but never increase the hospital cost.
What problem does this paper attempt to address?